Panbela Therapeutics, Inc.
PBLA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $26 | $36 | $10 | $6 |
| Gross Profit | -$26 | -$36 | -$10 | -$6 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $28 | $5 | $3 |
| G&A Expenses | $5 | $6 | $5 | $3 |
| SG&A Expenses | $5 | $6 | $5 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $34 | $10 | $6 |
| Operating Income | -$51 | -$34 | -$10 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $26 | -$1 | -$1 | $1 |
| Pre-Tax Income | -$25 | -$35 | -$11 | -$5 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$25 | -$35 | -$10 | -$5 |
| % Margin | – | – | – | – |
| EPS | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| % Growth | -470.4% | -96.2% | -40.4% | – |
| EPS Diluted | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$26 | $0 | $0 | $0 |
| EBITDA | -$51 | -$35 | -$11 | -$5 |
| % Margin | – | – | – | – |